Furthermore, we tested whether the PPARa agonist fenofibrate, which regulates many genes related to inflammation and lipid metabolism, including apoCIII, could reduce susceptibility to NAFLD. Here, APOC3 is linked to metabolic dysfunction-associated steatotic liver disease.